France – under the business-minded administration of President Emmanuel Macron – has been rapidly climbing investor priority rankings in recent years.

This report examines the potential impact of a swathe of ambitious recently-approved reforms and a new mood of optimism sweeping the country. These stand to impact the entire strategic direction of the French industry by taking private sector concerns much more into account, revitalizing the country’s industrial manufacturing base, boosting the growth prospects of its SMEs and repositioning France as an “innovation nation.”

This report features the exclusive comments of key stakeholders across the French healthcare value chain, including the global heads of French heavyweights Ipsen and Sanofi Pasteur, as well as government ministers, regulators, heads of pharma MNC affiliates, and representatives from the medtech and biotech industries.